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Background/Purpose:Weupdate the pre-clinical and early clinical results using a novel endovascular approach, to
perform chemical renal denervation, via peri-adventitial injection of micro-doses of dehydrated alcohol
(ethanol–EtOH).
Methods/Materials:Anovel, three-needle delivery device (Peregrine™)was used to denervate the renal arteries of
adult swine (n= 17) and in a ﬁrst-in-man feasibility study (n= 18). In the pre-clinical testing EtOHwas infused
bilaterally with one infusion per renal artery into to the perivascular space, using EtOH doses of 0.3 ml/artery
(n= 8), and 0.6 ml/artery (n= 9), and with saline sham control (0.4 ml/artery n= 3). Renal parenchymal nor-
epinephrine (NE) concentration (performed blindly), and safety were the primary endpoints. Data from the ﬁrst-
in-man study (n = 18) to evaluate device performance, safety and peri-procedural pain are reported.
Results: In the pre-clinical testing renal function was unchanged at 3-month follow-up. Angiography at 90 days
(n= 34 arteries) demonstrated normal appearing renal arteries, unchanged from baseline, andwithout stenosis
or other abnormalities. The reductions inmean renal parenchymal NE reductions at 3 months were 68% and 88%
at doses of 0.3 and 0.6 ml, respectively (p b 0.001 vs. controls). In the ﬁrst-in-man study, there was 100% device
success, no complications, a mean treatment time of 4.3 ± 3 minutes/artery, and minimal or no patient discom-
fort during treatment. Angiography at 6-months showed no evidence of renal artery stenosis, and evidence of a
reduction of blood pressure from baseline.
Conclusion:PerivascularRDNusingmicro-dosesof alcohol is apromisingalternative toenergy-based systems toachieve
dose-dependent, predictable, safe and essentially painless renal denervation. Further clinical evaluation is warranted.
Summary: (For annotated table of contents) This paper describes the preclinical results, in a porcinemodel, and the
early ﬁrst-in-man results, using the Peregrine™ chemical renal denervation catheter to perform renal sympathetic
denervation using micro-doses of alcohol.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In the 1930s–1950s surgical renal sympathectomywas used to treat
severe hypertension [1–3]. More recently, catheter-based renal sympa-
thetic denervation has been performed using a point-by-point, mono-
polar radiofrequency (RF) ablation catheter from the lumen of the
renal artery to treat patients [4–11]. This technique has been shown to
disrupt renal sympathetic nerve activity [4–7], resulting in signiﬁcantr these studies.
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. This is an open access article underand sustained reduction in ofﬁce-based blood pressure in patients
with severe and medically resistant hypertension [4–11].
Despite this early success, the concept of renal sympathetic nerve
denervation (RDN) as a means to treat resistant hypertension has
been challenged by the recent negative efﬁcacy results from the
Symplicity HTN-3 trial [12]. However, before dismissing renal denerva-
tion, it is important to understand that there are signiﬁcant issues with
radiofrequency, point-by-point ablation that may limit efﬁcacy and the
ability to predictably achieve adequate levels of renal sympathetic nerve
denervation. These shortcomings include pain, limited nerve ablation
depth [13], a risk of stenosis and intimal thrombus formation related
tomedial thermal injury [14–18], aswell as inconsistent and unpredict-
able circumferential denervation. Second generation, energy-based,
multi-electrode radiofrequency and ultrasound ablation concepts may
decrease pain burden and procedure time, but may not resolve the in-
herent limitations related to thermal injury to themedia, depth and ad-
equacy of denervation, and pain [19,20].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tive infusion of a potent neurolytic agent, such as alcohol, into the
perivascular (adventitial) space, has the potential to minimize intimal
andmedial vessel injurywhile providing circumferential, deep and con-
sistent renal sympathetic denervation. The encouraging short-term re-
sults using alcohol for renal denervation in a porcine model were
recently reported [21].
The longer-term preclinical studies, presented in this paper, demon-
strate that alcohol delivered locally and precisely to the adventitial and
peri-adventitial space produces a sustained, profound and predictable
reduction in renal parenchymal norepinephrine levels, with histopath-
ological evidence of circumferential, and deep (typically 7–12 mm
deep to the intima) sympathetic nerve injury, and with sparing of the
normal constituents of the renal artery wall. The early results from the
ﬁrst in man clinical study, presented here demonstrate safety, ease of
use, lack of pain, and the feasibility of this approach.
2. Materials and methods
2.1. Preclinical studies
A novel, three needle-based delivery device, (Peregrine System™,
Ablative Solutions, Inc., Kalamazoo, MI) was introduced via the femoral
artery into renal arteries of adult swine using ﬂuoroscopic guidance.
This drug infusion catheter is an endovascular delivery catheter that
contains three distal needles housed within individual guide tubes,
which are contained within body of the catheter. The catheter has a
steerable, radio-opaque 2 cm ﬁxed, ﬂoppy guide-wire at its distal end
to minimize renal artery trauma and allow steer ability, when needed,
into appropriate branch vessels (Fig. 1).
This study was conducted under the general principles of Good Lab-
oratory Practice (GLP) regulations as set forth in 21 CFR 58. The protocol
for this study was reviewed and approved by the IACUC of the test facil-
ity, which is accredited by AALAC and licensed by the USDA. Animals
were pre-medicated with 325 mg of aspirin and 75 mg of clopidogrel
by mouth once daily for 2 days before the procedure.
After the animals were prepared for sterile surgery, one femoral ar-
tery was accessed using the Seldinger technique, and a 7 French intro-
ducer was placed. Intravenous heparin was given to all animals to
achieve an ACT of N250 sec. In all cases the right and left renal arteriesFig. 1. Images of Peregrine™ device. In panel A the actual device is shown in the deployed
state with the guide tubes and needles opened at 120° one to the other and ﬂuid being
injected from the handle to the tips of the needles. White arrows show the ﬂexible
ﬁxed-wire tip. Panel B shows schematic of the device deployed in a renal arterywith alco-
hol (blue) being injected into the adventitial and peri-adventitial space. Yellow arrows
show deployed guide tubes and black arrows depict tips of deployed needles. Panel C
shows the ﬂuoroscopic image of the deployed device with radio-opaque markers at tip
of guide tubes and radio-opaque needles.of the pig were engaged using a 7 French RDC-1 guiding catheter.
Prior to infusion of either ethanol or saline injections, angiography of
each renal artery was performed using iohexol contrast diluted by 25%
with normal saline.
The Peregrine™ injection catheter is intended to be used under ﬂuo-
roscopic guidance by a single-operator using standard endovascular
techniques and to allow safe and reproducible ﬂuid injection into the
adventitial and peri-adventitial space of a target vessel (Fig. 2). The
0.008” needles that reside within the distal tip of the catheter's guide
tubes are advanced to a depth of 3.5 ± 0.25 mm deep to the intima
(i.e., beyond the tip of the guide tube) and at 120° separation, one nee-
dle to the others. The specialized handle, allows advancement of the
three guiding tubes, followed by simultaneous advancement of the
three injection needles into the adventitial space. These tiny needles
aremade radiopaque, so that they can be easily seen under ﬂuoroscopy.
The needles are the equivalent of a ~30 gauge needle so that they can be
safely advanced through the renal arterial wall without causing bleed-
ing, even after heparin administration [19]. The alcohol (ethanol) is de-
livered through a luer-lock connector at the proximal end of the handle,
resulting in the infusion of the alcohol through the tips of the three
needles of the Peregrine™ catheter, and directly into the perivascular,
adventitial and peri-adventitial space. This creates a reproducible,
deep and circumferential delivery of alcohol to the perivascular space
(Fig. 3).
In both the pre-clinical and clinical studies, the successful deploy-
ment of the tubes and needles are conﬁrmed by ﬂuoroscopy (Figs. 1
and 2). The radio-opacity of the guide tube tips and of the needles al-
lows visual conﬁrmation of the exact placement of the needle tips and
prevents the potential for injection into the lumen. In the porcine
study the EtOH or saline (sham) ﬂuid was then administered, using a
1.0 ml luer-lock syringe attached to the proximal injection lumen at
the handle of the catheter. The infusion is performed over 1–2 minutes.
Two volumes of EtOH were used in this study: 0.3 ml/artery (n= 8
pigs/16 arteries) and 0.6 ml/artery (n=9pigs/18 arteries). A procedur-
al control group was also studied using the infusion of 0.4 ml of saline/
artery (n= 3). This was a “sham” arm to control for nonspeciﬁc effects
that might be caused by mechanical injury from either the guide tubes
or the needles, and/or any non-speciﬁc effects of ﬂuid delivery. Once
the treatment agent was infused, the dead space of the catheter was
ﬂushed with a very small volume of normal saline (0.1 ml) to clear
the dead space and ensure delivery of the agent. After treatment of
the ﬁrst renal artery the devicewas removed from the animal, inspected
and ﬂushed. The contra-lateral renal artery was then engaged, and the
same ﬂuid infusion sequence was performed in the contralateral renal
artery. After the treatment of the second renal artery, the animals
were recovered and housed for restudy and sacriﬁce at 3-months
post-intervention. The animals were treated with aspirin 162 mg/day
for seven days after intervention.
Histopathologywas used to evaluate circumferential spread of alcohol
by having the pathologist evaluate and document the location (in terms
of circumference and depth) of any noted neuritis and neurolysis. The pa-
thologists were blinded as to the treatment (control, alcohol or naïve).
The efﬁcacy of denervation was assessed by measurement of renal
parenchymal norepinephrine (NE) levels (analyzed by HPLC, with elec-
trochemical detection), aswell as histopathologic evaluation of the peri-
renal nerves at the end of the three-month sacriﬁce period. Safety was
evaluated by serial blood tests for renal function, 45 and 90-day angio-
graphic studies, and histopathologic evaluation of the renal artery and
kidney. At the end of the study period the animals were anesthetized,
and angiography of the treated right and left renal arteries was per-
formed to evaluate vessel patency and to look for any luminal
narrowing, or other abnormalities as compared to baseline angiogra-
phy. Evaluation of the angiograms was conducted in a blinded fashion
by the angiographic core lab.
After angiographic follow-up a necropsy was performed. The renal
arteries and kidneys were harvested for histopathological evaluation.
Fig. 2. Angiography of renal arteries baseline, during deployment of the Peregrine System™, and at 90-day follow-up. A and D show the pre-treatment renal arteries. Panels B and E show
the angiographic image of the Peregrine System™ at the time of infusion. Panels C and F show 90-day angiographic ﬁndings in these two animals treated with 0.30 ml EtOH. There is no
detectable luminal narrowing or other abnormality.
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formed to look for renal artery abnormalities such as aneurysms, perfo-
rations, dissections, hematoma, etc., as well as inspection of the
surrounding tissues for any abnormalities. The renal arteries were can-
nulated, ﬂushed and perfused with formalin while in-situ. The renal ar-
teries and the kidneys were harvested, retaining the peri-adventitial
tissue around the artery. The renal artery tissuewas embedded in paraf-
ﬁn using standard techniques. Each renal artery was evaluated in at
three locations; proximal, mid and distal. Tissue was stained with H&E
and Movat s pentachrome. Microscopic evaluation was conducted in a
blinded fashion.Fig. 3. Evidence of circumferential delivery and axial distribution of ﬂuid after infusion
with Peregrine System™. In panel A, a lateral view is shown in a porcinemodel after injec-
tion of 0.4 ml of contrast plus + saline. Red circle illustrates location of media. This dem-
onstrates the circumferential distribution of ﬂuid delivery in the adventitia from the three
needles of the Peregrine System™ at the time of injection. Panel B shows the gross pathol-
ogy shortly after the injection of 0.15ml of ethanol admixedwith 0.15mlmethylene blue,
showing circumferential spread with as well as well as ~ 1.5 cm long axial spread.Prior to euthanasia of each animal, the kidneys were isolated, and
four samples were obtained from random locations at each of the prox-
imal, mid and distal regions of each kidney for a total of 12 samples/kid-
ney. The tissue samples were weighed, placed in cryovials and ﬂashed
frozen by immersion into dry ice. The frozen samples were then stored
at−70oC. They were sent in dry ice to an independent laboratory for
(blinded) measurement of renal parenchymal norepinephrine levels.
Renal norepinephrine concentrations in the treated animals from
this study were also compared to values from naïve control animals of
the same age and species (n= 8)with renal tissue sampling performed
in an identical fashion to the treated animals.
2.2. First-in-Man Study
The protocol for this studywas approved by the local ethics commit-
tee (Republic of Paraguay) and conducted in accordance with local reg-
ulations and statutes. Patients were enrolled in the study only after
giving written informed consent. This was a pilot study performed in
patients with refractory or “resistant” hypertension, using the same def-
inition of refractory hypertension, as deﬁned in the Symplicity studies
[12]. Patients were enrolled after careful screening and a 4-week run
in period to measure serial ofﬁce-based BP. All study patients were
treated with maximally tolerated doses of at least three anti-
hypertensive medications.
Eighteen patients were enrolled in the study and underwent bilater-
al renal artery denervation using the Peregrine™ device with a dose of
0.3 ml/artery. Only modest conscious sedation was used such that
pain scores could be assessed during the alcohol infusions. Pain was
assessed using a standard numeric pain rating scale (0 = no pain;
10= severe pain) scoring system using verbal interaction with the pa-
tient in real-time at the time of start of the infusion and then repeated
every 60 seconds after the infusion, until the complete resolution of
pain (0/10).
Patient safety was assessed by serial measurement of BUN, Cr, and
eGFR and by follow-up bilateral renal angiography at 6-month follow-
up. Ofﬁce-based BP was measured prior to intervention (×2) and then
Fig. 4. Bar graph showing the dose-response effect of adventitial EtOH delivery upon renal
parenchymal norepinephrine level at 90 days. There is a marked and dose-dependent re-
duction of NE levels versus both naive control animals and sham control animals injected
with saline. Mean NE reduction was 68% with 0.3 ml (n = 8) and 91% using 0.6 ml/artery
(n=9). Standard deviation (SD) for eachdata set as shown. Pb 0.001 for both 0.3 ml/artery
and 0.6 ml/artery treatments vs. both naive and sham (saline) controls.
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compliance was challenging in this study due to the demographics of
this patient population studied, and a language barrier.
For statistical analysis, between-group comparisons were made
using aWilcoxon rank-sum test, performed in R (Version 2.14.1, Vienna,
Austria). Data are shown in graphs asmean±SD.A p value of b0.05was
considered signiﬁcant.
3. Results
3.1. Preclinical results
Device success was deﬁned as successful infusion of the designated
ﬂuidwithout serious adverse events. In the porcine experiments the de-
vice was used successfully in all 20 animals and 40 renal arteries. Proce-
dure time, measured from the advancement of the device into the renal
artery, followed by deployment of tubes, then needles, injection, ﬂush-
ing, retraction of needles and tubes, and withdrawal back into the guid-
ing catheter averaged approximately 90 seconds for each renal artery.
There was no study-related morbidity or mortality. There were no
cases in which the anatomy precluded successful device delivery.
There were no dissections, perforations, extramural hematomas,
thrombus formation or other device-related complications. Mild to
moderate spasm was noted in some of the arteries but appeared to re-
solve slowly during limited observation, did not impair antegrade
renal blood ﬂow, and was completely absent at 45 day and 3-month
follow-up.
Measurements of renal tissue NE showed a highly signiﬁcant, and
dose-related reduction in renal parenchymal NE levels at threemonths,
comparing both the 0.3 ml/artery-treated animals (p b 0.001) and the
0.6 ml/artery-treated animal (p b 0.0001) vs. the sham treated and
true (untreated) controls. The mean renal NE reductions were 68%
and 88% at doses of 0.3 ml/artery, and 0.6 ml/artery, respectively
(p b 0.001 vs. combined controls) (Fig. 4).
Angiographic follow-up of all the 32 alcohol-treated vessels at 90 ±
5 days showed no evidence of renal artery narrowing at EtOH doses of
0.3 or 0.6 ml/artery (Fig. 2C, F). There were no other abnormalities
noted, including no aneurysmal changes or thrombus.
Histological examination revealed marked, deep, and circumferen-
tial renal nerve injury at depths of up to 13.4 mm from the intimal sur-
face (Fig. 5). There was no discernible nerve injury in the sham animal,
infusedwith saline (Fig. 5C, D). Nerve injury in the EtOH-treated vessels
was characterized by vacuolization, loss of internal architecture, and the
development peri-neural ﬁbrosis (Fig. 5B). Nerve injury appearedpermanent and with damage to the perineural sheath that would pre-
vent nerve regeneration.
Histopathology revealed no evidence of device-related or
EtOH-induced injury to the intimal layer of treated vessels (Fig. 5A).
There were no thrombi, dissections, aneurysms, perforations, hemato-
mas, neointimal formation, negative remodeling or other device-
related pathology.
At both 0.3 and 0.6 ml/artery doses therewas occasional, focal pallor
of some smooth muscle cells in the outermost layer of the media, typi-
cally originating at the adventitial surface and in close proximity to
the injection sites. At some of these sites there was focal proteoglycan
deposition. Inﬂammatory responses were absent at 3-months, and the
vessels appeared to be healing normally, without evidence of ﬁbrosis.
There was no evidence of negative remodeling observed in any treated
vessel. There was no discernible collateral injury to tissue deep to the
peri-adventitial plane, including the kidney, adrenals, bowel, etc.
There were no adverse nephrotoxic or systemic effects seen. The pigs's
serumcreatinine, BUN and electrolytes remainedwithin normal and ex-
pected limits over the study period.
3.2. First in man
All 18 patients were treated successfully with bilateral renal dener-
vation using the Peregrine device. One patient had a relatively large ac-
cessory renal artery (~5 mm diameter), which was treated in addition
to the main renal artery. Thus, a total of 37 renal arteries were treated
in the FIM experience. Device success was 100%, and there were no
acute adverse events noted. Speciﬁcally, there was no signiﬁcant bleed-
ing, spasm, thrombus formation, dissection, slow ﬂow, or other adverse
events observed.
The patients tolerated the procedure well with minimal conscious
sedation (Midazolam 5 mg & Fentanyl 50 μg). Patients were queried
during the alcohol injection and were asked to rate their discomfort/
pain on a 0–10 scale. The majority of infusions were performed with
the patients reporting no pain (23 infusions or 62%). Mild pain (score
of 1–3) ormoderate pain (score of 4–6)was reported during 6 infusions
(16%) each. Severe pain (score of 7 to 10) was reported during 2 infu-
sions (5%). The discomfort/pain was transient, with no pain being re-
ported within 1–2 minutes after the infusion. With slower infusion
rates (60–90 seconds) no pain was observed in the ﬁnal 8 patients.
Follow-up at 3 and 6-months demonstrated excellent renal safety,
with no change in BUN, Cr, or eGRF. No other trends were recognized
in the remaining clinical chemistry values. One patient expired at
9 weeks (67 days) post treatment during hospitalization for a
vascular-related mesenteric infarction. Corrective surgery was per-
formed, but the patient developed septic shock and death. This signiﬁ-
cant adverse event was reviewed by the principal investigator, and
was determined to be unrelated to either the Peregrine device or proce-
dure. One patient was lost to follow-up after the 3-month evaluation.
All remaining 16 patients had follow-up bilateral renal angiography
at ~6months post-intervention. A core lab performed post-hoc, blinded
assessment of the angiographic images from the procedures, and
follow-up angiography. No patient had any renal artery abnormality at
follow-up. The renal arteries were unchanged from baseline. There
were no vessels with any narrowing of N10% diameter stenosis at the
treatment site (n = 32 renal arteries) (Fig. 6).
The vast majority of patients, 88%, whowere evaluated had a reduc-
tion in blood pressure from baseline to the 6-month time point. There
was a mean reduction of −27 +/−5 mmHg (systolic), and −12
+/−4 mmHg (diastolic BP) among the 16 patients at 6-month
follow-up. This reduction in blood pressure occurred while themajority
of patients reduced the number of anti-hypertensive medications they
were taking (mean−1.2 medication reduction per patient). No patient
in this trial required an increase in the number of anti-hypertensive
medications. A number of the patients had substantial BP lowering in
the face of substantial reduction of antihypertensive medications
Fig. 5.Histopathology (H & E) of renal denervation at 14 days with 0.3 ml EtOH injection (A and B) vs. sham control (C and D). The renal artery (intima andmedia) appear intact without
evidence of injury or inﬂammation. The reaction to the EtOH is circumferential and limited to the adventitial layers (A and B). There is no apparent damage to the nerveﬁbers in the saline-
injected sample (C and D).
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reviewed, and prepared as a separate manuscript and are not within
the intended scope of this review.
4. Discussion
Hypertension is a common condition associated with signiﬁcant
morbidity including stroke, heart failure, myocardial infarction, renal
failure, and reduction in cardiovascular events. Importantly, observed
morbidity andmortality in patients with poor BP control is signiﬁcantly
higher than in those patients in whom blood pressure can be well con-
trolled. Therefore, alternative methods to supplement medical therapy
have been explored as early as the 1930s [1–3].
Renal sympathetic nerve denervation, using primarily radiofrequen-
cy (RF) mediated “thermal injury” to denervate the renal arteries in
humanshas shownearly evidenceof efﬁcacy in loweringbloodpressureFig. 6. Angiographic images from ﬁrst-in-man study. Anatomically challenging, short (9.8 mm
only a very short "landing zone" to deliver circumferential chemical renal denervation (panel A
graphic follow-up with no lesions or narrowing. 32/32 renal arteries treated in this study werein patients with “refractory” hypertension [4–11]. Second generation RF
devices have also demonstrated efﬁcacy and safety in BP lowering
[19,20].
Endovascular radiofrequency (RF) energy application with a unipo-
lar single electrode catheter has been accompanied by signiﬁcant ofﬁce-
based blood reductions and important, but smaller ambulatory blood
pressure reductions in both uncontrolled studies, and in a randomized
non-blinded trial [4–7].
More recently, the negative results from the randomized, sham-
controlled Medtronic Symplicity-HTN 3 trial [12] have left some casual
observers skeptical about the promise of renal denervation as a means
to manage hypertension.
However, some experts in the ﬁeld have begun to shed light on the
potential causes of the trial's failure. It has become increasingly clear
that one of the problemswith RF-mediated renal denervation is poor ef-
ﬁcacy related to the treatment procedure leading to unpredictable,long) main-stem, left renal artery, treated easily with Peregrine™ catheter which requires
). Panel B shows deployment of Peregrine™ catheter. Figure C shows the 6-month angio-
normal and unchanged from baseline at 6-month angiographic follow-up.
Fig. 7. Examples of ofﬁce-based pressure lowering at 1, 3 and 6 months in patients from ﬁrst-in-man study. In the ﬁrst patient (graph on left) the patient was taking 4 antihypertensive
medications at baseline, with a reduction to 3 medication at 3 and 6 months (51 mmHg drop in SBP and 8 mmHg drop in diastolic BP). In the second patient (graph on right) the patient
was taking 3 antihypertensive medications at baseline, with a reduction to 1 medication at 3 and 6 months (47 mmHg drop in SBP and 33 mmHg drop in diastolic BP).
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denervation.” [13,22]. “Non-responders” are not necessarily unrespon-
sive to renal sympathetic denervation. They may just be inadequately
denervated [22].
RF-based ablation from the intima, in a point-by-point, or even
multipoint array suffers from the number of limitations, including inad-
equate depth of neurolysis [13]. Porcine studies and a recent human au-
topsy report suggest that themaximum depth of nerve injury is as little
as 2 mm from the intimal surface, and potentially less in diseased arter-
ies [13]. This may lead to the possibility of “missing” more than half of
the sympathetic nerves [23,24]. There is also a likely lack of circumfer-
ential neurolysis, since each point ablation typically creates only a
~30–400 arc of damage [13]. Thus, with an average of only 3.8 ablations,
as was done in the Symplicity HTN-3 trial, one can estimate that as little
as 120–1600 arc of the renal artery is being treated. With the combined
lack of depth and a lack of circumferential coverage, it is likely that
4–6 “burns”may achieve as little as 20–30% denervation in themajority
of cases.
The anatomical challenges related to RDN with the RF-based ap-
proach are also supported by a recent analysis of the Symplicity-HTN
3 data by Kandzari, et al. [22]. These data show a dose-response to RF,
such that patients receiving 4–6 ablations have essentially no BP lower-
ing effect vs. the sham group. BP lowering was not observed until one
performed 7–9, or greater, ablations per artery. This may pose a major
challenge to the second generation RF “spiral” ablation concept, since
a smallminority of patients have the 4–5 cm long renal arteries required
to safely achieve this threshold number of “spiral” ablations, unless one
performsdenervation inmuch smaller, distal branch vessels. This “distal
branch vessel” approach has been proposed, butmay pose a greater risk
of late renal artery stenosis in these smaller (2.5–3.5 mm diameter)
branch vessels.
Alternatively, chemical renal denervation, as described in this paper,
using micro-doses of dehydrated alcohol (ethanol) has been evaluated
in preclinical and early clinical studies. This approach may overcome
many of the serious limitations of energy-based denervation.
Alcohol has beenwell established as an excellent neurolytic agent in
a wide range of clinical specialties and may be especially well suited for
renal denervation. Even at very low concentrations it may exert a local
anesthetic effect. At higher concentrations, as was used in these studies,
it causes denaturation of essential cellular proteins, and membrane
damage by extraction of phospholipids, cholesterol and cerebrosides
[25–29]. Damage to the perineural sheath at these dosesmay also effec-
tively help prevent nerve regeneration.The Peregrine™ infusion catheter has been extensively tested in a
porcine model to deliver micro-doses of ethanol to the adventitia
(Fig. 1). This catheter is now FDA 510 K cleared for the infusion of diag-
nostic or therapeutic agents into the perivascular space. The device s
three 0.008” needles are deployed simultaneously, at 120-degrees, one
to another at a depth of ~3.5 mm measured from the intima. At this
depth the needle tips are located in the adventitia, and thus in very
close proximity to the sympathetic nerve ﬁbers. Alcohol doses of 0.3
and 0.6 ml consistently achieve ~65–92% nerve inactivation, as evi-
denced by drops in renal parenchymal norepinephrine measurements,
and by histopathological evaluation. Histopathologic examination after
alcohol infusion demonstrates essentially complete, circumferential
neurolysis at depths of up to 7–14 mm from the intimal surface [21].
In the early human experience, with 18 patients treated in the ﬁrst
human use study, there were signiﬁcant BP reductions in the vast ma-
jority of patients, typically in the face of a reduction of antihypertensive
medications. The delivery of 0.3 ml of ethanol to the adventitia in these
patients was also essentially painless, which offers a major advantage
over treatment with thermal ablation catheters. Importantly, there
was 100% device success, short procedure times, no adverse events
and no evidence of renal artery narrowing or other changes at
6-months of follow-up.
Taking the aforementioned limitations of energy-based renal dener-
vation concepts into account, renal denervation by catheter-based
perivascular alcohol injection may have a number of advantages. First,
tissue injury of the intima and media, that is common to energy-based
systems is minimized or eliminated usingmicro-needles that penetrate
3–4 mm deep to the intimal surface of the renal artery, and with distri-
bution of alcohol limited to the adventitia and perivascular space. Sec-
ond, uniformly circumferential nerve damage at depths of 7–14 mm is
routinely achieved with ethanol injection, providing more consistent
and complete denervation. Third, in the absence of medial injury, peri-
procedural pain is typically essentially absent, thus requiring minimal
analgesia and sedation. In addition, there are virtually no limitations
to the length of the renal artery that can be treated, and few limitations
to the diameter or angle of renal artery take-off (Fig. 6). The procedure is
very efﬁcient with a very short procedural time. Finally, no generator or
accessory capital equipment is required, thus limiting procedural costs.
5. Conclusions
In summary, chemical renal denervation using ethanolmay have ad-
vantages over energy-based “thermal” technologies, including, an
227T.A. Fischell et al. / Cardiovascular Revascularization Medicine 16 (2015) 221–227ability to get predictable circumferential nerve kill at substantial depth,
to achieve efﬁcient, complete and predictable denervation with mini-
mal anatomical limitations, and without a need for capital equipment.
This approach also allows one to target the nerves where they are locat-
ed (in the adventitia), and thus minimize injury to the intima and
media. Finally, in contrast to RF or ultrasound ablation this approach ap-
pears to be essentially painless. Additional clinical evaluations are un-
derway to better deﬁne the safety and efﬁcacy of this promising “next
generation” technology for renal sympathetic denervation.
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